Join Apeloa at CPHI Frankfurt for Innovative Pharma Solutions
Join Apeloa at CPHI Frankfurt 2025
Greetings from the heart of the pharmaceutical industry! This week, Apeloa Pharmaceutical, a top provider of technology-driven manufacturing solutions, is thrilled to invite you to visit our booth number 9.1B64 at CPHI Frankfurt 2025. This event, which run from October 28–30, serves as a platform for industry leaders to unite and explore cutting-edge innovations.
Engaging with Apeloa
We encourage you to reach out to our dedicated team during the event to discuss how our end-to-end services can enhance your projects and expedite development timelines.
Showcasing Our Advanced Technology Platforms
At Apeloa, we harness advanced technology to propel our services in Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) manufacturing. Some key platforms we will showcase include:
Greener Molecules Through Flow Chemistry
Apeloa’s cutting-edge flow chemistry techniques are reshaping the paradigms of pharmaceutical processing. This approach significantly reduces the time required for key reactions, achieving a staggering 99% reduction in reaction time for cephalosporin intermediates—from 8 hours to under 5 minutes. Additionally, this innovation slashes Process Mass Intensity (PMI) by 53% and cuts energy usage in half. Ideal for high-risk and hazardous reactions, our flow chemistry is developed with over a decade of research and the expertise of more than 50 scientists.
Next-Gen Bioconjugates and ADCs
In the realm of bioconjugates, Apeloa excels in providing high-purity linkers to facilitate the development of Antibody-Drug Conjugates (ADCs) and peptide drugs. Our services encompass:
- Monodisperse PEG Synthesis: We supply high-purity PEGs with a polydispersity index of 1.00, catering to both R&D and multi-kilogram requirements.
- Specialized Linkers: Our extensive library includes various linkers, such as PEG, clickable, and MAL Linkers, with modifications to optimize efficacy and stability.
CDMO Services and API Solutions
Apeloa’s advanced technology forms the backbone of our core offerings, allowing seamless collaboration with global partners.
- Comprehensive CDMO Services: Our one-stop service covers the entire drug development lifecycle, empowering clients with affordable medication delivery. From research preparation to commercial production, we ensure tailored and adaptable manufacturing solutions.
- Leading Global API Supplier: Apeloa stands out as a prominent API supplier with a well-integrated supply chain spanning from intermediates to final dosage forms. Our diverse portfolio supports a range of therapeutic areas, including anti-infectives and diabetes, underscored by our rigorous quality assurance.
About Apeloa
Founded in 1989, Apeloa has solidified its position as a key player in the pharmaceutical sector, recognized as one of China's foremost API exporters and a leading CDMO. Our rich history is backed by a commitment to excellence and feedback driven improvements supported by our advanced R&D facilities across Boston, Shanghai, and Hengdian. With a dedicated workforce of over 1,300 scientists, we commit to delivering high-quality products that meet global standards.
Get in touch with us directly at press@hengdian.com.
Frequently Asked Questions
What is Apeloa's role at CPHI Frankfurt 2025?
Apeloa is showcasing its innovative technologies and services in pharmaceutical manufacturing solutions.
Where is Apeloa's booth located?
You can find Apeloa at Booth 9.1B64 during CPHI Frankfurt 2025.
What advanced technologies does Apeloa offer?
Apeloa offers technologies like flow chemistry for faster reactions and high-purity linkers for bioconjugate development.
How can I contact Apeloa?
You can reach Apeloa through their email at press@hengdian.com.
What is Apeloa's history?
Founded in 1989, Apeloa is one of China’s leading pharmaceutical manufacturers and API exporters with a rich history of quality and innovation.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.